Regeneron Pharmaceuticals (REGN) Payables (2009 - 2026)

Regeneron Pharmaceuticals' Payables history runs 18 years deep, the most recent figure standing at $1.2 billion for Q2 2026.

• In Q2 2026, Payables rose 60.15% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $1.2 billion (up 60.15% YoY), while the FY2025 annual figure was $939.0 million, up 18.94% from the prior year.
• Payables for Q2 2026 stood at $1.2 billion, up from $1.0 billion in the prior quarter.
• The five-year high for Payables was $1.2 billion in Q2 2026, with the low at $470.3 million in Q1 2022.
• The 5-year median for Payables is $603.0 million (2023), against an average of $688.8 million.
• The sharpest annual moves came in 2022 and 2025: Payables fell 13.37% in 2022, then jumped 81.74% in 2025.
• Regeneron Pharmaceuticals' Payables stood at $589.2 million in 2022, then advanced by 2.95% to $606.6 million in 2023, then soared by 30.15% to $789.5 million in 2024, then advanced by 18.94% to $939.0 million in 2025, then gained by 23.46% to $1.2 billion in 2026.
• Business Quant data shows REGN's Payables at $1.2 billion in Q2 2026, $1.0 billion in Q1 2026, and $939.0 million in Q4 2025.